A Phase 2 interventional study of zilucoplan (RA101495) and Placebo in Generalized Myasthenia Gravis, sponsored by Ra Pharmaceuticals. Completed at 30 sites in 2 countries. Open to participants aged 18 Years to 85 Years. Per ClinicalTrials.gov, last updated 2022-07-27.
Sponsored by Ra Pharmaceuticals (part of UCB S.A.) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 18 studies in Myasthenia Gravis by UCB S.A. — 5 open to participants now, 7 under way, 5 of them phase 3. Myasthenia Gravis · UCB S.A..
Among the 18 studies in Myasthenia Gravis by UCB S.A., this one is the 9th largest by enrollment, is one of 2 that started in 2017, is one of 2 in phase 2, and was the 2nd registered.
331 studies on the registry are indexed under Myasthenia Gravis; 144 are open to participants now.
Browse Myasthenia Gravis studies →5 of the 18 studies in Myasthenia Gravis by UCB S.A. are open now, in 12 countries. Recruiting first, the newest first:
UCB Biopharma SRL · Sites in United States, China, France and 4 more countries
Ages 18+
UCB Biopharma SRL · Sites in United States, Canada, China and 6 more countries
Ages 18+
Candid Therapeutics · Sites in China
Ages 18+
UCB Biopharma SRL · Sites in United States, Italy, Poland and 2 more countries
Ages 12–17
UCB Biopharma SRL · Sites in Italy, Poland, Korea, Republic of and 1 more country
Ages 12+
By country, each count listing its studies:
Of the 104 Myasthenia Gravis studies recruiting now, 64 (62%) set no upper age limit and 23 (22%) stop at 75 or younger; 16 take children under 18; 13 take healthy volunteers.
This study: 18 Years to 85 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
18 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 4 · Phase 3 14 · Phase 4 1
First in 2017; this study’s year is marked. 2 started in 2017.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 45 is close to the median of 44 across 217 interventional studies indexed under Myasthenia Gravis.
Median enrollment 45 across the 18 interventional studies. Of the 11 that completed or were terminated, 9 (82%) have results posted.
This tab as a report to print or save as PDF → With an account.
This study is registered under Ra Pharmaceuticals, one of the names counted as UCB S.A.. Under that name alone:
Ra Pharmaceuticals is the lead sponsor of 4 studies on the registry; none are open to participants now.
4 of the studies in Myasthenia Gravis by UCB S.A. that are under way reach primary completion within a year, 3 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06055959Phase 3UCB Biopharma SRLA Study to Evaluate Subcutaneous Zilucoplan in Pediatric Participants With Generalized Myasthenia Gravis | 2027-05-12 |
| NCT06540144Phase 3UCB Biopharma SRLAn Extension Study Evaluating 6-week Treatment Cycles of Rozanolixizumab in Pediatric Study Participants With Generalized Myasthenia Gravis | 2027-10-05 |
| NCT06435312Phase 3UCB Biopharma SRLAn Open-label Extension Study to Evaluate Subcutaneous Zilucoplan in Pediatric Participants With Generalized Myasthenia Gravis | 2027-10-26 |
| NCT07246564UCB Biopharma SRLPhase 4 Study Evaluating Efficacy and Safety of Rozanolixizumab in Adult Chinese Participants With Generalized Myasthenia Gravis | 2027-10-15 |
Add all 4 to your calendar (.ics) → With an account.
Among the 18 studies in Myasthenia Gravis by UCB S.A., from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of the study is to evaluate the safety and efficacy of RA101495 in patients with generalized Myasthenia Gravis (gMG). Subjects will be randomized in a 1:1:1 ratio to receive daily SC doses of 0.1 mg/kg RA101495, 0.3 mg/kg RA101495, or matching placebo for 12 weeks.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: zilucoplan (RA101495)
Drug: zilucoplan (RA101495)
Drug: Placebo
Daily subcutaneous (SC) injection
Daily subcutaneous (SC) injection
Main Portion: Change From Baseline to Week 12 in Quantitative Myasthenia Gravis (QMG) Score
The QMG is a standardized and validated quantitative strength scoring system that was developed specifically for myasthenia gravis (MG). The scale consists of 13 individual assessments, each scored on a 0-3 point scale (i.e., 0=none, 1=mild, 2=moderate, and 3=severe). The total score is the sum of the individual scores with a range of 0-39. Higher scores are representative of more severe impairment.
Time frame: From Baseline to Week 12
Main Portion: Change From Baseline to Week 12 in the Myasthenia Gravis - Activities of Daily Living (MG-ADL) Scale
The MG-ADL is a brief 8-item survey designed to evaluate MG symptom severity. The scale consists of 8 items each scored on a 0-3 point scale (i.e., 0=none, 1=mild, 2=moderate, and 3=severe). The total score is the sum of the 8 individual scores with range of 0-24. Higher scores are associated with more severe symptoms of MG.
Time frame: From Baseline to Week 12
Main Portion: Change From Baseline to Week 12 in the Myasthenia Gravis - Quality of Life 15r (MG-QOL15r) Survey
The MG-QOL15r is a 15-item survey that was designed to assess quality of life in participants with MG. The survey consisted of 15 questions and the corresponding responses were each scored on a 0-2 point scale (0=Not much at all, 1=Somewhat, 2=Very Much). The total score is the sum of the 15 individual item scores with a range of 0-30. Higher scores indicate more severe impact of the disease on aspects of the participant's life.
Time frame: From Baseline to Week 12
Main Portion: Change From Baseline to Week 12 in the MG Composite Scale Total Score
The MG Composite is a 10-item scale that has been used to measure the clinical status of participants with MG, in order to evaluate treatment response. It consists of 10 items which included ptosis (score range=0 to 3), double vision on lateral gaze left/right/both (score range=0 to 4), eye closure (score range=0 to 2), talking (score range=0 to 6), chewing (score range=0 to 6), swallowing (score range=0 to 6), breathing (score range=0 to 9), neck flexion or extension (score range=0 to 4), shoulder abduction (score range=0 to 5) and hip flexion (score range= 0 to 5). The total score is the sum of the 10 individual scores with a range of 0-50. Higher scores in the MG Composite indicate more severe impairment due to the disease.
Time frame: From Baseline to Week 12
Main Portion: Percentage of Participants With >= 3-point Reduction in QMG Total Score at Week 12
The QMG is a standardized and validated quantitative strength scoring system that was developed specifically for MG. The scale consists of 13 individual assessments, each scored on a 0-3 point scale (i.e., 0=none, 1=mild, 2=moderate, and 3=severe). The total score is the sum of the individual scores with a range of 0-39. Higher scores are representative of more severe impairment.
Time frame: Week 12
Main Portion: Percentage of Participants Who Required Rescue Therapy Over the 12-week Treatment Period
Percentage of participants who used at least 1 dose of rescue medication were reported.
Time frame: Up to Week 12
Main Portion: Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)
An adverse event (AE) is any untoward medical occurrence in a participant or clinical investigation participant administered a pharmaceutical product, which does not necessarily have a causal relationship with this treatment. An AE could therefore be any unfavorable and unintended sign, symptom, or disease temporally associated with the use of a medicinal (investigational) product, whether or not related to the medicinal (investigational) product. A serious adverse event (SAE) is any untoward medical occurrence that at any dose resulted in death, life-threatening, significant or persistent disability/incapacity, congenital anomaly/birth defect, important medical event, initial inpatient hospitalization or prolongation of hospitalization.
Time frame: From Baseline to Week 12
Main Portion: Change From Baseline in Sheep Red Blood Cell (sRBC) Lysis Assay at Week 12 (Pre-dose)
A BioTek ELx800 automated microplate reader is used to measure the optical density at 415 nanometer (nm) of human plasma samples to calculate the percent lysis of sheep erythrocytes that has occurred as a result of total complement activity. The measure of complement activity is determined by the degree of hemolysis of the erythrocytes.
Time frame: Baseline and Week 12 (Pre-dose)
Main Portion: Change From Baseline in C5 Levels at Week 12 (Pre-dose)
Blood samples were collected from participants to assess Complement Component 5C levels.
Time frame: Baseline and Week 12 (Pre-dose)
Main Portion: Plasma Concentration of RA101495 and Its Major Metabolites
RA102758 and RA103488 are the metabolites of RA101495.
Time frame: 1, 3 and 6 hours postdose on Day 1; Pre-dose on Week 1, 2, 4, 8 and 12
Main Portion: Maximum Plasma Concentration (Cmax) on Day 1
Cmax is defined as the maximum observed plasma concentration.
Time frame: Pre-dose, 1, 3 and 6 hours postdose on Day 1
Main Portion: Time Corresponding to Cmax (Tmax) on Day 1
Tmax is defined as the time to observe maximum plasma concentration.
Time frame: Pre-dose, 1, 3 and 6 hours postdose on Day 1
Main Portion: Metabolites (RA102758 and RA103488) to Parent Ratio
RA102758 and RA103488 are the metabolites of RA101495.
Time frame: Pre-dose, 1, 3 and 6 hours postdose on Day 1; Pre-dose on Week 1, 2, 4, 8 and 12
The study started to enroll participants in October 2017 and concluded in November 2020.
| Milestone | RA101495 0.1 mg/kg | RA101495 0.3 mg/kg | Placebo | RA101495 0.1 mg/kg (Before Switch) to 0.3 mg/kg (After Switch) |
|---|---|---|---|---|
| Started | 15 | 15 | 15 | 0 |
| Completed | 15 | 13 | 15 | 0 |
| Not completed | 0 | 2 | 0 | 0 |
| Withdrew: Subject withdrew consent | 0 | 1 | 0 | 0 |
| Withdrew: Lost to follow-up | 0 | 1 | 0 | 0 |
| Milestone | RA101495 0.1 mg/kg | RA101495 0.3 mg/kg | Placebo | RA101495 0.1 mg/kg (Before Switch) to 0.3 mg/kg (After Switch) |
|---|---|---|---|---|
| Started | 22 | 21 | 0 | 0 |
| Completed | 21 | 21 | 0 | 0 |
| Not completed | 1 | 0 | 0 | 0 |
| Withdrew: Subject withdrew consent | 1 | 0 | 0 | 0 |
| Milestone | RA101495 0.1 mg/kg | RA101495 0.3 mg/kg | Placebo | RA101495 0.1 mg/kg (Before Switch) to 0.3 mg/kg (After Switch) |
|---|---|---|---|---|
| Started | 0 | 21 | 0 | 21 |
| Completed | 0 | 17 | 0 | 20 |
| Not completed | 0 | 4 | 0 | 1 |
| Withdrew: Withdrawal by subject | 0 | 1 | 0 | 0 |
| Withdrew: Subject withdrew consent | 0 | 1 | 0 | 0 |
| Withdrew: Death | 0 | 2 | 0 | 1 |
The QMG is a standardized and validated quantitative strength scoring system that was developed specifically for myasthenia gravis (MG). The scale consists of 13 individual assessments, each scored on a 0-3 point scale (i.e., 0=none, 1=mild, 2=moderate, and 3=severe). The total score is the sum of the individual scores with a range of 0-39. Higher scores are representative of more severe impairment.
| score on a scale | RA101495 0.1 mg/kg (mITT) | RA101495 0.3 mg/kg (mITT) | Placebo (mITT) |
|---|---|---|---|
| Main Portion: Change From Baseline to Week 12 in Quantitative Myasthenia Gravis (QMG) Score | -5.5 ± 1.2 | -6.0 ± 1.2 | -3.2 ± 1.2 |
The MG-ADL is a brief 8-item survey designed to evaluate MG symptom severity. The scale consists of 8 items each scored on a 0-3 point scale (i.e., 0=none, 1=mild, 2=moderate, and 3=severe). The total score is the sum of the 8 individual scores with range of 0-24. Higher scores are associated with more severe symptoms of MG.
| score on a scale | RA101495 0.1 mg/kg (mITT) | RA101495 0.3 mg/kg (mITT) | Placebo (mITT) |
|---|---|---|---|
| Main Portion: Change From Baseline to Week 12 in the Myasthenia Gravis - Activities of Daily Living (MG-ADL) Scale | -3.3 ± 0.9 | -3.4 ± 0.9 | -1.1 ± 0.9 |
The MG-QOL15r is a 15-item survey that was designed to assess quality of life in participants with MG. The survey consisted of 15 questions and the corresponding responses were each scored on a 0-2 point scale (0=Not much at all, 1=Somewhat, 2=Very Much). The total score is the sum of the 15 individual item scores with a range of 0-30. Higher scores indicate more severe impact of the disease on aspects of the participant's life.
| score on a scale | RA101495 0.1 mg/kg (mITT) | RA101495 0.3 mg/kg (mITT) | Placebo (mITT) |
|---|---|---|---|
| Main Portion: Change From Baseline to Week 12 in the Myasthenia Gravis - Quality of Life 15r (MG-QOL15r) Survey | -7.4 ± 1.7 | -5.9 ± 1.7 | -2.1 ± 1.7 |
The MG Composite is a 10-item scale that has been used to measure the clinical status of participants with MG, in order to evaluate treatment response. It consists of 10 items which included ptosis (score range=0 to 3), double vision on lateral gaze left/right/both (score range=0 to 4), eye closure (score range=0 to 2), talking (score range=0 to 6), chewing (score range=0 to 6), swallowing (score range=0 to 6), breathing (score range=0 to 9), neck flexion or extension (score range=0 to 4), shoulder abduction (score range=0 to 5) and hip flexion (score range= 0 to 5). The total score is the sum of the 10 individual scores with a range of 0-50. Higher scores in the MG Composite indicate more severe impairment due to the disease.
| score on a scale | RA101495 0.1 mg/kg (mITT) | RA101495 0.3 mg/kg (mITT) | Placebo (mITT) |
|---|---|---|---|
| Main Portion: Change From Baseline to Week 12 in the MG Composite Scale Total Score | -5.3 ± 1.5 | -7.4 ± 1.6 | -3.3 ± 1.6 |
The QMG is a standardized and validated quantitative strength scoring system that was developed specifically for MG. The scale consists of 13 individual assessments, each scored on a 0-3 point scale (i.e., 0=none, 1=mild, 2=moderate, and 3=severe). The total score is the sum of the individual scores with a range of 0-39. Higher scores are representative of more severe impairment.
| percentage of participants | RA101495 0.1 mg/kg (mITT) | RA101495 0.3 mg/kg (mITT) | Placebo (mITT) |
|---|---|---|---|
| Main Portion: Percentage of Participants With >= 3-point Reduction in QMG Total Score at Week 12 | 66.7 | 71.4 | 53.3 |
Percentage of participants who used at least 1 dose of rescue medication were reported.
| percentage of participants | RA101495 0.1 mg/kg (mITT) | RA101495 0.3 mg/kg (mITT) | Placebo (mITT) |
|---|---|---|---|
| Main Portion: Percentage of Participants Who Required Rescue Therapy Over the 12-week Treatment Period | 6.7 | 0 | 20.0 |
An adverse event (AE) is any untoward medical occurrence in a participant or clinical investigation participant administered a pharmaceutical product, which does not necessarily have a causal relationship with this treatment. An AE could therefore be any unfavorable and unintended sign, symptom, or disease temporally associated with the use of a medicinal (investigational) product, whether or not related to the medicinal (investigational) product. A serious adverse event (SAE) is any untoward medical occurrence that at any dose resulted in death, life-threatening, significant or persistent disability/incapacity, congenital anomaly/birth defect, important medical event, initial inpatient hospitalization or prolongation of hospitalization.
| Participants | RA101495 0.1 mg/kg (SS) | RA101495 0.3 mg/kg (SS) | Placebo (SS) |
|---|---|---|---|
| AEs | 15 | 12 | 14 |
| SAEs | 0 | 5 | 3 |
A BioTek ELx800 automated microplate reader is used to measure the optical density at 415 nanometer (nm) of human plasma samples to calculate the percent lysis of sheep erythrocytes that has occurred as a result of total complement activity. The measure of complement activity is determined by the degree of hemolysis of the erythrocytes.
| percent lysis of sheep erythrocytes | RA101495 0.1 mg/kg (PD) | RA101495 0.3 mg/kg (PD) | Placebo (PD) |
|---|---|---|---|
| Main Portion: Change From Baseline in Sheep Red Blood Cell (sRBC) Lysis Assay at Week 12 (Pre-dose) | -81.822 ± 2.469 | -94.914 ± 2.908 | 0.775 ± 2.571 |
Blood samples were collected from participants to assess Complement Component 5C levels.
| micrograms/milliliter (ug/mL) | RA101495 0.1 mg/kg (PD) | RA101495 0.3 mg/kg (PD) | Placebo (PD) |
|---|---|---|---|
| Main Portion: Change From Baseline in C5 Levels at Week 12 (Pre-dose) | 57.349 ± 7.057 | 54.302 ± 6.804 | -2.774 ± 6.237 |
RA102758 and RA103488 are the metabolites of RA101495.
| nanograms/milliliter (ng/mL) | RA101495 0.1 mg/kg (PK) | RA101495 0.3 mg/kg (PK) |
|---|---|---|
| RA101495- Day 1: 1 hour postdose | 652.136 ± 354.652 | 2272.257 ± 1246.128 |
| RA101495- Day 1: 3 hours postdose | 1691.267 ± 469.766 | 4176.000 ± 1211.166 |
| RA101495- Day 1: 6 hours postdose | 1925.357 ± 330.335 | 4636.000 ± 809.804 |
| RA101495- Week 1: Pre-dose | 4571.214 ± 719.566 | 9223.786 ± 2365.168 |
| RA101495- Week 2: Pre-dose | 4914.200 ± 743.215 | 10222.846 ± 1662.869 |
| RA101495- Week 4: Pre-dose | 5100.286 ± 859.767 | 10265.917 ± 1604.004 |
| RA101495- Week 8: Pre-dose | 5222.067 ± 688.427 | 10075.000 ± 1872.400 |
| RA101495- Week 12: Pre-dose | 5281.333 ± 1122.372 | 10284.846 ± 1771.586 |
| RA102758- Day 1: 1 hour postdose | NA ± NA | NA ± NA |
| RA102758- Day 1: 3 hours postdose | NA ± NA | NA ± NA |
| RA102758- Day 1: 6 hours postdose | NA ± NA | NA ± NA |
| RA102758- Week 1: Pre-dose | 252.693 ± 78.909 | 849.743 ± 273.388 |
| RA102758- Week 2: Pre-dose | 408.847 ± 94.773 | 1473.431 ± 440.496 |
| RA102758- Week 4: Pre-dose | 462.486 ± 180.098 | 1567.692 ± 557.745 |
| RA102758- Week 8: Pre-dose | 474.073 ± 157.549 | 1432.808 ± 530.377 |
| RA102758- Week 12: Pre-dose | 465.665 ± 195.227 | 1459.062 ± 451.013 |
| RA103488- Day 1: 1 hour postdose | NA ± NA | NA ± NA |
| RA103488- Day 1: 3 hours postdose | NA ± NA | NA ± NA |
| RA103488- Day 1: 6 hours postdose | NA ± NA | 85.832 ± 257.664 |
| RA103488- Week 1: Pre-dose | 356.186 ± 162.209 | 838.907 ± 255.419 |
| RA103488- Week 2: Pre-dose | 501.847 ± 218.467 | 1135.731 ± 270.004 |
| RA103488- Week 4: Pre-dose | 536.266 ± 275.013 | 1191.783 ± 251.853 |
| RA103488- Week 8: Pre-dose | 615.740 ± 229.359 | 1234.708 ± 201.055 |
| RA103488- Week 12: Pre-dose | 621.813 ± 241.354 | 1307.492 ± 331.553 |
Cmax is defined as the maximum observed plasma concentration.
| ng/mL | RA101495 0.1 mg/kg (PK) | RA101495 0.3 mg/kg (PK) |
|---|---|---|
| Main Portion: Maximum Plasma Concentration (Cmax) on Day 1 | 1945.467 ± 407.273 | 4858.643 ± 1004.457 |
Tmax is defined as the time to observe maximum plasma concentration.
| hours | RA101495 0.1 mg/kg (PK) | RA101495 0.3 mg/kg (PK) |
|---|---|---|
| Main Portion: Time Corresponding to Cmax (Tmax) on Day 1 | 4.550 (2.95 to 5.50) | 4.700 (2.62 to 5.92) |
RA102758 and RA103488 are the metabolites of RA101495.
| ratio | RA101495 0.1 mg/kg (PK) | RA101495 0.3 mg/kg (PK) |
|---|---|---|
| RA102758/RA101495- Day 1: Pre-dose | NA ± NA | NA ± NA |
| RA102758/RA101495- Day 1: 1 hour postdose | 0.000 ± 0.000 | 0.000 ± 0.000 |
| RA102758/RA101495- Day 1: 3 hours postdose | 0.000 ± 0.000 | 0.000 ± 0.000 |
| RA102758/RA101495- Day 1: 6 hours postdose | 0.000 ± 0.000 | 0.013 ± 0.044 |
| RA102758/RA101495- Week 1: Pre-dose | 0.121 ± 0.033 | 0.202 ± 0.038 |
| RA102758/RA101495- Week 2: Pre-dose | 0.182 ± 0.038 | 0.307 ± 0.057 |
| RA102758/RA101495- Week 4: Pre-dose | 0.197 ± 0.072 | 0.323 ± 0.072 |
| RA102758/RA101495- Week 8: Pre-dose | 0.195 ± 0.057 | 0.301 ± 0.070 |
| RA102758/RA101495- Week 12: Pre-dose | 0.184 ± 0.065 | 0.303 ± 0.061 |
| RA103488/RA101495- Day 1: Pre-dose | NA ± NA | NA ± NA |
| RA103488/RA101495- Day 1: 1 hour postdose | 0.000 ± 0.000 | 0.000 ± 0.000 |
| RA103488/RA101495- Day 1: 3 hours postdose | 0.000 ± 0.000 | 0.001 ± 0.001 |
| RA103488/RA101495- Day 1: 6 hours postdose | 0.000 ± 0.000 | 0.015 ± 0.045 |
| RA103488/RA101495- Week 1: Pre-dose | 0.079 ± 0.037 | 0.099 ± 0.044 |
| RA103488/RA101495- Week 2: Pre-dose | 0.104 ± 0.044 | 0.114 ± 0.037 |
| RA103488/RA101495- Week 4: Pre-dose | 0.106 ± 0.046 | 0.119 ± 0.038 |
| RA103488/RA101495- Week 8: Pre-dose | 0.118 ± 0.044 | 0.127 ± 0.040 |
| RA103488/RA101495- Week 12: Pre-dose | 0.116 ± 0.035 | 0.131 ± 0.041 |
Collected over From Baseline up to Week 122. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Main Portion: RA101495 0.1 mg/kg | 0/15 (0%) | 0/15 (0%) | 15/15 (100%) |
| Main Portion: RA101495 0.3 mg/kg | 0/14 (0%) | 5/14 (35.7%) | 12/14 (85.7%) |
| Main Portion: Placebo | 0/15 (0%) | 3/15 (20%) | 14/15 (93.3%) |
| Main and Extension Portion: RA101495 0.1 mg/kg Before Switch to 0.3 mg/kg | 1/22 (4.5%) | 5/22 (22.7%) | 22/22 (100%) |
| Main and Extension Portion: RA101495 0.1 mg/kg After Switch to 0.3 mg/kg | 0/21 (0%) | 4/21 (19%) | 17/21 (81%) |
| Main and Extension Portion: RA101495 0.3 mg/kg | 2/21 (9.5%) | 11/21 (52.4%) | 21/21 (100%) |
| Event | Main Portion: RA101495 0.1 mg/kg | Main Portion: RA101495 0.3 mg/kg | Main Portion: Placebo | Main and Extension Portion: RA101495 0.1 mg/kg Before Switch to 0.3 mg/kg | Main and Extension Portion: RA101495 0.1 mg/kg After Switch to 0.3 mg/kg | Main and Extension Portion: RA101495 0.3 mg/kg |
|---|---|---|---|---|---|---|
| Worsening of Myasthenia GravisNervous system disorders | 0/15 | 0/14 | 3/15 | 0/22 | 0/21 | 0/21 |
| Pancreas infectionInfections and infestations | 0/15 | 0/14 | 0/15 | 0/22 | 0/21 | 2/21 |
| Post procedural complicationInjury, poisoning and procedural complications | 0/15 | 0/14 | 0/15 | 0/22 | 0/21 | 2/21 |
| CholecystitisHepatobiliary disorders | 0/15 | 0/14 | 0/15 | 0/22 | 0/21 | 2/21 |
| PneumoniaInfections and infestations | 0/15 | 0/14 | 0/15 | 2/22 | 1/21 | 1/21 |
| CellulitisInfections and infestations | 0/15 | 1/14 | 0/15 | 0/22 | 0/21 | 1/21 |
| Abdominal abscessInfections and infestations | 0/15 | 1/14 | 0/15 | 0/22 | 0/21 | 1/21 |
| DiverticulitisInfections and infestations | 0/15 | 1/14 | 0/15 | 0/22 | 0/21 | 1/21 |
| Systemic inflammatory response syndromeGeneral disorders | 0/15 | 1/14 | 0/15 | 0/22 | 0/21 | 1/21 |
| Blood culture positiveInvestigations | 0/15 | 1/14 | 0/15 | 0/22 | 0/21 | 1/21 |
| Event | Main Portion: RA101495 0.1 mg/kg | Main Portion: RA101495 0.3 mg/kg | Main Portion: Placebo | Main and Extension Portion: RA101495 0.1 mg/kg Before Switch to 0.3 mg/kg | Main and Extension Portion: RA101495 0.1 mg/kg After Switch to 0.3 mg/kg | Main and Extension Portion: RA101495 0.3 mg/kg |
|---|---|---|---|---|---|---|
| HeadacheNervous system disorders | 6/15 | 3/14 | 4/15 | 10/22 | 3/21 | 4/21 |
| NasopharyngitisInfections and infestations | 1/15 | 0/14 | 0/15 | 6/22 | 5/21 | 8/21 |
| Injection site bruisingGeneral disorders | 2/15 | 0/14 | 2/15 | 6/22 | 0/21 | 3/21 |
| DizzinessNervous system disorders | 1/15 | 0/14 | 4/15 | 4/22 | 3/21 | 3/21 |
| Back painMusculoskeletal and connective tissue disorders | 1/15 | 1/14 | 1/15 | 2/22 | 0/21 | 5/21 |
| NauseaGastrointestinal disorders | 2/15 | 0/14 | 0/15 | 4/22 | 1/21 | 5/21 |
| DiarrhoeaGastrointestinal disorders | 1/15 | 1/14 | 1/15 | 2/22 | 0/21 | 5/21 |
| CoughRespiratory, thoracic and mediastinal disorders | 0/15 | 0/14 | 0/15 | 3/22 | 1/21 | 5/21 |
| Injection site scabGeneral disorders | 3/15 | 0/14 | 0/15 | 3/22 | 0/21 | 0/21 |
| Upper respiratory tract infectionInfections and infestations | 0/15 | 0/14 | 0/15 | 3/22 | 2/21 | 4/21 |
Intent-to-Treat (ITT) population included all randomized participants.
| Age, Categorical(Participants) | RA101495 0.1 mg/kg | RA101495 0.3 mg/kg | Placebo | Total |
|---|---|---|---|---|
| <=18 years | 0 | 0 | 0 | 0 |
| Between 18 and 65 years | 14 | 11 | 13 | 38 |
| >=65 years | 1 | 4 | 2 | 7 |
| Age, Continuous(years) | RA101495 0.1 mg/kg | RA101495 0.3 mg/kg | Placebo | Total |
|---|---|---|---|---|
| Mean | 45.5 ± 15.6 | 54.5 ± 14.9 | 48.4 ± 15.7 | 49.5 ± 15.5 |
| Sex: Female, Male(Participants) | RA101495 0.1 mg/kg | RA101495 0.3 mg/kg | Placebo | Total |
|---|---|---|---|---|
| Female | 8 | 5 | 11 | 24 |
| Male | 7 | 10 | 4 | 21 |
| Race/Ethnicity, Customized(Participants) | RA101495 0.1 mg/kg | RA101495 0.3 mg/kg | Placebo | Total |
|---|---|---|---|---|
| Asian | 0 | 1 | 1 | 2 |
| Black or African American | 2 | 3 | 2 | 7 |
| White | 13 | 11 | 12 | 36 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Oct 2017 to primary completion in Dec 2018, 13 months.
Results were first posted in Jun 2022, 3 years 6 months after primary completion. A results delay was requested in Aug 2020.
Of 22 phase 2 interventional studies under Myasthenia Gravis, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 30. This study's 13 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Zilucoplan